Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Eri T. Kato"'
Autor:
Kyohei, Yamaji, Hiroki, Shiomi, Takeshi, Morimoto, Yukiko, Matsumura-Nakano, Natsuhiko, Ehara, Hiroki, Sakamoto, Yasuaki, Takeji, Yusuke, Yoshikawa, Ko, Yamamoto, Eri T, Kato, Kazuaki, Imada, Takeshi, Tada, Ryoji, Taniguchi, Ryusuke, Nishikawa, Tomohisa, Tada, Takashi, Uegaito, Tatsuya, Ogawa, Miho, Yamada, Teruki, Takeda, Hiroshi, Eizawa, Nobushige, Tamura, Keiichi, Tambara, Satoru, Suwa, Manabu, Shirotani, Toshihiro, Tamura, Moriaki, Inoko, Junichiro, Nishizawa, Masahiro, Natsuaki, Hiroshi, Sakai, Takashi, Yamamoto, Naoki, Kanemitsu, Nobuhisa, Ohno, Katsuhisa, Ishii, Akira, Marui, Hiroshi, Tsuneyoshi, Yasuhiko, Terai, Shogo, Nakayama, Kazuhiro, Yamazaki, Mamoru, Takahashi, Takashi, Tamura, Jiro, Esaki, Shinji, Miki, Tomoya, Onodera, Hiroshi, Mabuchi, Yutaka, Furukawa, Masaru, Tanaka, Tatsuhiko, Komiya, Yoshiharu, Soga, Michiya, Hanyu, Takenori, Domei, Kenji, Ando, Kazushige, Kadota, Kenji, Minatoya, Yoshihisa, Nakagawa, Takeshi, Kimura
Publikováno v:
JACC. Asia. 2(3)
Diabetes is a well-known risk factor for adverse outcomes after coronary revascularization.This study sought to determine high-risk subgroups in whom the excess risks of diabetes relative to nondiabetes are particularly prominent and thus may benefit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ade092196f47569180e241c2190955ed
https://pubmed.ncbi.nlm.nih.gov/36411876
https://pubmed.ncbi.nlm.nih.gov/36411876
Autor:
Erika Yamamoto, Cabg Registry Cohort, Ko Yamamoto, Naritatsu Saito, Takeshi Kimura, cohort investigators, Kenji Ando, Satoru Suwa, Takeshi Tada, Yusuke Yoshikawa, Kazushige Kadota, Mph Eri T. Kato, Hirotoshi Watanabe, Yasuaki Takeji, Ryuzo Nawada, Toshihiro Tamura, Yutaka Furukawa, Katsuhisa Ishii, Yoshihisa Nakagawa, Tomoya Onodera, Takenori Domei, Yukiko Matsumura-Nakano, CREDO-Kyoto Pci, Hiroki Shiomi, Mph Takeshi Morimoto
Publikováno v:
JACC. Asia. 1(3)
[Background] There are limited data on the long-term stent-related adverse events as related to the duration of dual antiplatelet therapy (DAPT) in second-generation (G2) drug-eluting stents (DES) compared with first-generation (G1) DES. [Objectives]
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5586f7ea371d2b5ff61434fb22056402
https://pubmed.ncbi.nlm.nih.gov/36341224
https://pubmed.ncbi.nlm.nih.gov/36341224
Autor:
Michelle L, O'Donoghue, Eri T, Kato, Ofri, Mosenzon, Sabina A, Murphy, Avivit, Cahn, Marisol, Herrera, Tsvetalina, Tankova, Alena, Šmahelová, Piera, Merlini, Ingrid, Gause-Nilsson, Anna Maria, Langkilde, Darren K, McGuire, John P H, Wilding, Larry A, Leiter, Deepak L, Bhatt, Itamar, Raz, Marc S, Sabatine, Stephen D, Wiviott
Publikováno v:
Diabetologia. 64(6)
Women remain underrepresented in clinical trials and those with type 2 diabetes mellitus are at high risk for cardiovascular (CV) events. The sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin reduces the risk of CV death or heart failure
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e108afa8ff4fe37a9ba99f24398ffc85
https://pubmed.ncbi.nlm.nih.gov/33611623
https://pubmed.ncbi.nlm.nih.gov/33611623
Autor:
Thomas A, Zelniker, Stephen D, Wiviott, Itamar, Raz, KyungAh, Im, Erica L, Goodrich, Remo H M, Furtado, Marc P, Bonaca, Ofri, Mosenzon, Eri T, Kato, Avivit, Cahn, Deepak L, Bhatt, Lawrence A, Leiter, Darren K, McGuire, John P H, Wilding, Marc S, Sabatine
Publikováno v:
Journal of Diabetes Investigation
Glucagon-like peptide 1 receptor agonists (GLP1-RA) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) have emerged as 2 new classes of antihyperglycemic agents that also reduce cardiovascular risk. The relative benefits in patients with and with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d544630d380152021033f01d2d413b64
https://pubmed.ncbi.nlm.nih.gov/31446675
https://pubmed.ncbi.nlm.nih.gov/31446675